|
UPPSALA, Sweden, Nov. 3, 2022 /PRNewswire/ -- Advancing the pipeline facilitating future growth Q3 2022 highlights Total net revenues of SEK 161.0 m (145.9) EBITDA of SEK -32.4 m (-47.4), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 14.3 m (-13.4) Net... |
